Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Maxer who wrote (527)	7/13/1998 2:39:00 PM
From: Anthony Wong	Respond to of 1722

Canada's Supreme Court Says Drug-Patent Rules Are 'Draconian' Bloomberg News July 11, 1998, 9:33 a.m. PT Canada's Supreme Court Says Drug-Patent Rules Are 'Draconian' Ottawa, July 11 (Bloomberg) -- Canada's Supreme Court has overturned a ruling that has kept two generic drugs supplied by Toronto-based drug makers Novopharm Ltd. and Apotex Ltd. off Canadian pharmacy shelves, the Globe and Mail reported. Low-cost generic versions of the drugs -- the antibiotic norfloxacin and an ulcer drug nizatidine -- have been kept off the Canadian market by litigation from brand-name drug companies Eli Lilly Canada Inc. of Toronto and Merck Frosst Canada Inc. of Kirkland, Quebec, which argued their expenses for time and research shouldn't be undermined by firms that then reproduce the drugs and sell them at a lower cost. Canada's nine supreme court judges ruled Friday ''to subject generic drug producers to such a Draconian regime would be manifestly unjust,'' the newspaper said. Eli Lilly & Co., Genentech Inc., Bristol-Myers Squibb Co. and others are working on treatments that would fight and prevent breast cancer, according to studies released at a spring medical meeting in Los Angeles. (G&M 7/11 B1. Online edition: www.theglobeandmail.com) --Corey Goldman in the Toronto newsroom (416) 364-7300/cvh